The United States

George Clinical now has substantial operations in the USA, with 42 staff and leaders in oncology trials both operationally and scientifically.

George Clinical in The United States

Tweet about this on TwitterShare on FacebookShare on LinkedIn

George Clinical, leading Asia-Pacific CRO, expands into US with acquisition of a specialised oncology CRO Division

Headquartered in Sydney, Australia, George Clinical has offices in China, India, Hong Kong, South Korea, Taiwan, Malaysia, New Zealand, United Kingdom, Czech Republic and now the USA.

Over the years, George Clinical has grown rapidly across the Asia-Pacific region and is continuing to develop global operations. The combination of a strong commercial proficiency and clinical research and scientific excellence positions George Clinical as a high quality, global CRO with substantial clinical and scientific assets.

George Clinical now has substantial operations in the USA, with 42 staff and leaders in oncology trials both operationally and scientifically. We are here to support our US customers with their CRO needs and to lead oncology trials across our core operational facilities in the Asia Pacific region.

George Clinical US Staff Locations

George Clinical US News

George Clinical, leading Asia-Pacific CRO, expands into US with acquisition of a specialised oncology CRO Division

George Clinical, a leading full-service CRO in the Asia-Pacific region and Vector Oncology, a Memphis-based leader in oncology research and data analytics, formally announced today that George Clinical has acquired Vector Oncology’s Pharma Services (CRO) Division…

New South Wales and China explore opportunities to grow in health and medical research

The NSW Minister for Health and Medical Research, The Honourable Brad Hazzard MP, visited The George Institute, China on 7 December with a health and medical delegation led by the Minister in China as part of the NSW-Guangdong Joint Economic Meeting (JEM) on 5 D...

New board member for The George Institute

The George Institute for Global Health welcomes the appointment of a new board member, Meena Thuraisingham.

Cases of heart failure continue to rise; poorest people worst affected

The number of people being diagnosed with heart failure in the UK continues to rise as a result of demographic changes common to many developed countries, new research by The George Institute for Global Health at the University of Oxford suggests.

Record $24 million for research into Australia's biggest killers

The George Institute for Global Health today received a landmark investment of $24 million from the Australian Government to undertake research to prevent and treat cardiometabolic diseases, which affect seven million Australians and hundreds of millions globally.

Academy Award for The George Institute’s Chief Scientist

Professor Anushka Patel’s outstanding contributions to the treatment and prevention of cardiovascular disease has been recognised today in the annual Australian Academy of Science honorific awards.

Study ends debate over best way to prevent acute kidney failure post angiogram

Treatments commonly used to prevent acute kidney failure and its complications arising from common angiography procedures make no difference to health outcomes, a major new study has found.

Details

Number of Personnel: 45
In-country Services: Business Development
Scientific Leadership
Oncology specialists
Project Management
Clinical Operations
Clinical Compliance
Regulatory Services
Medical and Safety management
Data Management
Statistics
Health Economics
Population: 321 million
Official Language: English 79.2%, Spanish 12.9%, other Indo-European 3.8%, Asian and Pacific island 3.3%, other 0.9%
Hospital Records Language: English

Twitter Facebook LinkedIn